Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

Background: Poor reporting compromises the reliability and clinical value of prognostic tumour marker studies. We review articles to assess the reporting of patients and events using REMARK guidelines, at the time of guideline publication. Methods: We sampled 50 prognostic tumour marker studies from...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Mallett, S, Timmer, A, Sauerbrei, W, Altman, D
Kolejni autorzy: Cancer Research UK
Format: Journal article
Język:English
Wydane: Nature Publishing Group 2010
Hasła przedmiotowe:
_version_ 1826263543410851840
author Mallett, S
Timmer, A
Sauerbrei, W
Altman, D
author2 Cancer Research UK
author_facet Cancer Research UK
Mallett, S
Timmer, A
Sauerbrei, W
Altman, D
author_sort Mallett, S
collection OXFORD
description Background: Poor reporting compromises the reliability and clinical value of prognostic tumour marker studies. We review articles to assess the reporting of patients and events using REMARK guidelines, at the time of guideline publication. Methods: We sampled 50 prognostic tumour marker studies from higher impact cancer journals between 2006 and 2007. The inclusion criteria were cancer; focus on single biological tumour marker; survival analysis; multivariable analysis; and not gene array or proteomic data. Articles were assessed for the REMARK profile and other REMARK guideline items. We propose a reporting aid, the REMARK profile, motivated by the CONSORT flowchart. Results: In 50 studies assessed for the REMARK profile, the number of eligible patients (56% of articles), excluded patients (54%) and patients in analyses (98%) was reported. Only 50% of articles reported the number of outcome events. In multivariable analyses, 54% and 30% of articles reported patient and event numbers for all variables. Of the studies, 66% used archival samples, indicating a potentially biased patient selection. Only 36% of studies reported clearly defined outcomes. Conclusions: Good reporting is critical for the interpretability and clinical applicability of prognostic studies. Current reporting of key information, such as the number of outcome events in all patients and subgroups, is poor. Use of the REMARK profile would greatly improve reporting and enhance prognostic research.
first_indexed 2024-03-06T19:53:27Z
format Journal article
id oxford-uuid:24c0d5dc-4c26-43b9-8f6e-90b4f4fc93e5
institution University of Oxford
language English
last_indexed 2024-03-06T19:53:27Z
publishDate 2010
publisher Nature Publishing Group
record_format dspace
spelling oxford-uuid:24c0d5dc-4c26-43b9-8f6e-90b4f4fc93e52022-03-26T11:51:52ZReporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelinesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:24c0d5dc-4c26-43b9-8f6e-90b4f4fc93e5Medical sciencesStatistics (see also social sciences)EnglishOxford University Research Archive - ValetNature Publishing Group2010Mallett, STimmer, ASauerbrei, WAltman, DCancer Research UKBackground: Poor reporting compromises the reliability and clinical value of prognostic tumour marker studies. We review articles to assess the reporting of patients and events using REMARK guidelines, at the time of guideline publication. Methods: We sampled 50 prognostic tumour marker studies from higher impact cancer journals between 2006 and 2007. The inclusion criteria were cancer; focus on single biological tumour marker; survival analysis; multivariable analysis; and not gene array or proteomic data. Articles were assessed for the REMARK profile and other REMARK guideline items. We propose a reporting aid, the REMARK profile, motivated by the CONSORT flowchart. Results: In 50 studies assessed for the REMARK profile, the number of eligible patients (56% of articles), excluded patients (54%) and patients in analyses (98%) was reported. Only 50% of articles reported the number of outcome events. In multivariable analyses, 54% and 30% of articles reported patient and event numbers for all variables. Of the studies, 66% used archival samples, indicating a potentially biased patient selection. Only 36% of studies reported clearly defined outcomes. Conclusions: Good reporting is critical for the interpretability and clinical applicability of prognostic studies. Current reporting of key information, such as the number of outcome events in all patients and subgroups, is poor. Use of the REMARK profile would greatly improve reporting and enhance prognostic research.
spellingShingle Medical sciences
Statistics (see also social sciences)
Mallett, S
Timmer, A
Sauerbrei, W
Altman, D
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title_full Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title_fullStr Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title_full_unstemmed Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title_short Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
title_sort reporting of prognostic studies of tumour markers a review of published articles in relation to remark guidelines
topic Medical sciences
Statistics (see also social sciences)
work_keys_str_mv AT malletts reportingofprognosticstudiesoftumourmarkersareviewofpublishedarticlesinrelationtoremarkguidelines
AT timmera reportingofprognosticstudiesoftumourmarkersareviewofpublishedarticlesinrelationtoremarkguidelines
AT sauerbreiw reportingofprognosticstudiesoftumourmarkersareviewofpublishedarticlesinrelationtoremarkguidelines
AT altmand reportingofprognosticstudiesoftumourmarkersareviewofpublishedarticlesinrelationtoremarkguidelines